Intellia Therapeutics, Inc.
NTLA · NASDAQ
Financial statements
Annual and quarterly income, balance-sheet, cash-flow and key-statistics data.
Income statement
| Period | Revenue | Gross profit | Operating income | Net income | EPS |
|---|---|---|---|---|---|
| 2022 FY | 52.12M | 44.55M | -458.16M | -474.19M | -6.16 |
| 2023 FY | 36.28M | 27.30M | -515.29M | -481.19M | -5.42 |
| 2024 FY | 57.88M | 47.59M | -534.26M | -519.02M | -5.25 |
| 2025 FY | 67.67M | 51.75M | -440.99M | -412.69M | -3.81 |
Balance sheet
| Period | Total assets | Liabilities | Cash | Debt | Equity |
|---|---|---|---|---|---|
| 2022 FY | 1.52B | 284.53M | 523.51M | 130.70M | 1.24B |
| 2023 FY | 1.30B | 250.81M | 226.75M | 115.35M | 1.05B |
| 2024 FY | 1.19B | 319.06M | 189.18M | 210.20M | 871.96M |
| 2025 FY | 842.13M | 170.73M | 155.46M | 93.33M | 671.39M |
Cash flow
| Period | Operating cash flow | Capital expenditure | Free cash flow | Dividends paid | Net cash change |
|---|---|---|---|---|---|
| 2022 FY | -333.29M | -58.39M | -391.68M | — | 409.98M |
| 2023 FY | -394.09M | -13.99M | -408.07M | — | -295.11M |
| 2024 FY | -348.88M | -5.78M | -354.66M | — | -37.57M |
| 2025 FY | -348.88M | -5.78M | -354.66M | — | -37.57M |
Key statistics
| Period | Market cap | Enterprise value | P/E | Price / sales | Debt / equity |
|---|---|---|---|---|---|
| 2022 FY | 2.69B | 2.29B | — | — | — |
| 2023 FY | 2.71B | 2.60B | — | — | — |
| 2024 FY | 1.15B | 1.17B | — | — | — |
| 2025 FY | 974.30M | 912.17M | — | — | — |
| 2026-12-31 | — | — | — | — | — |
| 2027-12-31 | — | — | — | — | — |
| 2028-12-31 | — | — | — | — | — |
Income statement
| Period | Revenue | Gross profit | Operating income | Net income | EPS |
|---|---|---|---|---|---|
| 2025 Q2 | 14.25M | -66.29M | -110.00M | -101.26M | -0.98 |
| 2025 Q3 | 13.78M | -65.17M | -111.48M | -101.32M | -0.92 |
| 2025 Q4 | 23.02M | 17.00M | -98.71M | -95.79M | -0.83 |
| 2026 Q1 | 15.05M | 12.85M | -100.53M | -96.23M | -0.81 |
Balance sheet
| Period | Total assets | Liabilities | Cash | Debt | Equity |
|---|---|---|---|---|---|
| 2025 Q2 | 898.89M | 183.64M | 156.17M | 102.59M | 715.26M |
| 2025 Q3 | 925.28M | 176.85M | 193.39M | 97.97M | 748.42M |
| 2025 Q4 | 842.13M | 170.73M | 155.46M | 93.33M | 671.39M |
| 2026 Q1 | 758.78M | 137.84M | 134.70M | 80.49M | 620.94M |
Cash flow
| Period | Operating cash flow | Capital expenditure | Free cash flow | Dividends paid | Net cash change |
|---|---|---|---|---|---|
| 2025 Q2 | -99.62M | -239.00K | -99.86M | — | 21.94M |
| 2025 Q3 | -76.90M | -29.00K | -76.93M | — | 37.22M |
| 2025 Q4 | -69.29M | -126.00K | -69.41M | — | -37.93M |
| 2026 Q1 | -117.35M | -79.00K | -117.43M | — | -20.77M |
Key statistics
| Period | Market cap | Enterprise value | P/E | Price / sales | Debt / equity |
|---|---|---|---|---|---|
| 2025 Q2 | 973.01M | 919.43M | — | — | — |
| 2025 Q3 | 1.90B | 1.81B | — | — | — |
| 2025 Q4 | 974.30M | 912.17M | — | — | — |
| 2026 Q1 | 1.52B | 1.46B | — | — | — |
| 2026-06-30 | — | — | — | — | — |
| 2026-09-30 | — | — | — | — | — |
| 2026-12-31 | — | — | — | — | — |